Brain-derived neurotrophic factor and autism: Maternal and infant peripheral blood levels in the early markers for autism (EMA) study

Lisa A. Croen, Paula Goines, Daniel Braunschweig, Robert Yolken, Cathleen K. Yoshida, Judith K. Grether, Bruce Fireman, Martin Kharrazi, Robin L Hansen, Judith A Van de Water

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

To investigate levels of brain-derived neurotrophic factor (BDNF) in mid-pregnancy and neonatal blood specimens as early biologic markers for autism, we conducted a population-based case-control study nested within the cohort of infants born from July 2000 to September 2001 to women who participated in the prenatal screening program in Orange County, CA. Cases (n584) were all children receiving services for autism at the Regional Center of Orange County. Two comparison groups from the same study population were included: children with mental retardation or developmental delay (n549) receiving services at the same regional center, and children not receiving services for developmental disabilities, randomly sampled from the California birth certificate files (n5159), and frequency matched to autism cases on sex, birth year, and birth month. BDNF concentrations were measured in archived mid-pregnancy and neonatal blood specimens drawn during routine prenatal and newborn screening using a highly sensitive bead-based assay (Luminex, Biosource Human BDNF Antibody Bead Kit, Invitrogen-Biosource, Carlsbad, CA). The concentration of BDNF in maternal mid-pregnancy and neonatal specimens was similar across all three study groups. These data do not support previous findings of an association between BDNF and autism and suggest that the concentration of BDNF during critical periods of early neurodevelopment is not likely to be a useful biomarker for autism susceptibility.

Original languageEnglish (US)
Pages (from-to)130-137
Number of pages8
JournalAutism Research
Volume1
Issue number2
DOIs
StatePublished - 2008

Fingerprint

Brain-Derived Neurotrophic Factor
Autistic Disorder
Mothers
Prenatal Diagnosis
Pregnancy
Biomarkers
Parturition
Birth Certificates
Developmental Disabilities
Intellectual Disability
Population
Case-Control Studies
Newborn Infant
Antibodies

Keywords

  • Autism
  • BDNF
  • Biologic markers
  • Neurotrophin
  • Prenatal

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Genetics(clinical)
  • Medicine(all)

Cite this

Brain-derived neurotrophic factor and autism : Maternal and infant peripheral blood levels in the early markers for autism (EMA) study. / Croen, Lisa A.; Goines, Paula; Braunschweig, Daniel; Yolken, Robert; Yoshida, Cathleen K.; Grether, Judith K.; Fireman, Bruce; Kharrazi, Martin; Hansen, Robin L; Van de Water, Judith A.

In: Autism Research, Vol. 1, No. 2, 2008, p. 130-137.

Research output: Contribution to journalArticle

Croen, LA, Goines, P, Braunschweig, D, Yolken, R, Yoshida, CK, Grether, JK, Fireman, B, Kharrazi, M, Hansen, RL & Van de Water, JA 2008, 'Brain-derived neurotrophic factor and autism: Maternal and infant peripheral blood levels in the early markers for autism (EMA) study', Autism Research, vol. 1, no. 2, pp. 130-137. https://doi.org/10.1002/aur.14
Croen, Lisa A. ; Goines, Paula ; Braunschweig, Daniel ; Yolken, Robert ; Yoshida, Cathleen K. ; Grether, Judith K. ; Fireman, Bruce ; Kharrazi, Martin ; Hansen, Robin L ; Van de Water, Judith A. / Brain-derived neurotrophic factor and autism : Maternal and infant peripheral blood levels in the early markers for autism (EMA) study. In: Autism Research. 2008 ; Vol. 1, No. 2. pp. 130-137.
@article{5b4cf23c16f64296b7d70121593a134c,
title = "Brain-derived neurotrophic factor and autism: Maternal and infant peripheral blood levels in the early markers for autism (EMA) study",
abstract = "To investigate levels of brain-derived neurotrophic factor (BDNF) in mid-pregnancy and neonatal blood specimens as early biologic markers for autism, we conducted a population-based case-control study nested within the cohort of infants born from July 2000 to September 2001 to women who participated in the prenatal screening program in Orange County, CA. Cases (n584) were all children receiving services for autism at the Regional Center of Orange County. Two comparison groups from the same study population were included: children with mental retardation or developmental delay (n549) receiving services at the same regional center, and children not receiving services for developmental disabilities, randomly sampled from the California birth certificate files (n5159), and frequency matched to autism cases on sex, birth year, and birth month. BDNF concentrations were measured in archived mid-pregnancy and neonatal blood specimens drawn during routine prenatal and newborn screening using a highly sensitive bead-based assay (Luminex, Biosource Human BDNF Antibody Bead Kit, Invitrogen-Biosource, Carlsbad, CA). The concentration of BDNF in maternal mid-pregnancy and neonatal specimens was similar across all three study groups. These data do not support previous findings of an association between BDNF and autism and suggest that the concentration of BDNF during critical periods of early neurodevelopment is not likely to be a useful biomarker for autism susceptibility.",
keywords = "Autism, BDNF, Biologic markers, Neurotrophin, Prenatal",
author = "Croen, {Lisa A.} and Paula Goines and Daniel Braunschweig and Robert Yolken and Yoshida, {Cathleen K.} and Grether, {Judith K.} and Bruce Fireman and Martin Kharrazi and Hansen, {Robin L} and {Van de Water}, {Judith A}",
year = "2008",
doi = "10.1002/aur.14",
language = "English (US)",
volume = "1",
pages = "130--137",
journal = "Autism Research",
issn = "1939-3806",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Brain-derived neurotrophic factor and autism

T2 - Maternal and infant peripheral blood levels in the early markers for autism (EMA) study

AU - Croen, Lisa A.

AU - Goines, Paula

AU - Braunschweig, Daniel

AU - Yolken, Robert

AU - Yoshida, Cathleen K.

AU - Grether, Judith K.

AU - Fireman, Bruce

AU - Kharrazi, Martin

AU - Hansen, Robin L

AU - Van de Water, Judith A

PY - 2008

Y1 - 2008

N2 - To investigate levels of brain-derived neurotrophic factor (BDNF) in mid-pregnancy and neonatal blood specimens as early biologic markers for autism, we conducted a population-based case-control study nested within the cohort of infants born from July 2000 to September 2001 to women who participated in the prenatal screening program in Orange County, CA. Cases (n584) were all children receiving services for autism at the Regional Center of Orange County. Two comparison groups from the same study population were included: children with mental retardation or developmental delay (n549) receiving services at the same regional center, and children not receiving services for developmental disabilities, randomly sampled from the California birth certificate files (n5159), and frequency matched to autism cases on sex, birth year, and birth month. BDNF concentrations were measured in archived mid-pregnancy and neonatal blood specimens drawn during routine prenatal and newborn screening using a highly sensitive bead-based assay (Luminex, Biosource Human BDNF Antibody Bead Kit, Invitrogen-Biosource, Carlsbad, CA). The concentration of BDNF in maternal mid-pregnancy and neonatal specimens was similar across all three study groups. These data do not support previous findings of an association between BDNF and autism and suggest that the concentration of BDNF during critical periods of early neurodevelopment is not likely to be a useful biomarker for autism susceptibility.

AB - To investigate levels of brain-derived neurotrophic factor (BDNF) in mid-pregnancy and neonatal blood specimens as early biologic markers for autism, we conducted a population-based case-control study nested within the cohort of infants born from July 2000 to September 2001 to women who participated in the prenatal screening program in Orange County, CA. Cases (n584) were all children receiving services for autism at the Regional Center of Orange County. Two comparison groups from the same study population were included: children with mental retardation or developmental delay (n549) receiving services at the same regional center, and children not receiving services for developmental disabilities, randomly sampled from the California birth certificate files (n5159), and frequency matched to autism cases on sex, birth year, and birth month. BDNF concentrations were measured in archived mid-pregnancy and neonatal blood specimens drawn during routine prenatal and newborn screening using a highly sensitive bead-based assay (Luminex, Biosource Human BDNF Antibody Bead Kit, Invitrogen-Biosource, Carlsbad, CA). The concentration of BDNF in maternal mid-pregnancy and neonatal specimens was similar across all three study groups. These data do not support previous findings of an association between BDNF and autism and suggest that the concentration of BDNF during critical periods of early neurodevelopment is not likely to be a useful biomarker for autism susceptibility.

KW - Autism

KW - BDNF

KW - Biologic markers

KW - Neurotrophin

KW - Prenatal

UR - http://www.scopus.com/inward/record.url?scp=67650173512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650173512&partnerID=8YFLogxK

U2 - 10.1002/aur.14

DO - 10.1002/aur.14

M3 - Article

C2 - 19119429

AN - SCOPUS:67650173512

VL - 1

SP - 130

EP - 137

JO - Autism Research

JF - Autism Research

SN - 1939-3806

IS - 2

ER -